Quackenbush Disease (Q‑Fever Endocarditis) – A Patient‑Friendly Guide
Overview
Quackenbush disease is a colloquial term for Q‑fever endocarditis, a chronic infection of the heart’s inner lining (the endocardium) caused by the bacterium Coxiella burnetii. The organism is the same pathogen that produces acute Q‑fever, a flu‑like illness acquired from livestock. When the infection persists, especially in people with pre‑existing valve disease, it can settle on heart valves and cause endocarditis.
- Who it affects: Primarily adults (median age 45‑55) with pre‑existing valvular abnormalities, prosthetic heart valves, or implanted cardiac devices.
- Gender: Slight male predominance (≈55 % men).
- Geography: Worldwide; higher incidence in agricultural regions of Europe, Australia, the United States, and parts of Asia where livestock farming is common.
- Prevalence: Q‑fever endocarditis is rare—accounting for <1 % of all endocarditis cases in the United States, but it represents up to 10 % of endocarditis in some endemic regions (e.g., French Guiana, the Netherlands). The overall seroprevalence of C. burnetii exposure ranges from 5‑40 % in farming communities.[1] CDC, 2023
Symptoms
Symptoms develop slowly over weeks to months, often masquerading as other cardiac or systemic illnesses. Below is a complete list with brief explanations.
Cardiac‑related symptoms
- Fever or low‑grade fever – persistent, often < 38 °C (100.4 °F).
- Heart murmur – new or worsening murmur due to valve damage.
- Palpitations – irregular beats caused by valve dysfunction.
- Chest pain – typically pleuritic or related to heart failure.
- Shortness of breath – may indicate developing heart failure.
- Peripheral edema – swelling of ankles/feet from fluid overload.
Systemic / constitutional symptoms
- Fatigue / weakness – most common and often severe.
- Weight loss – unintentional loss of >5 % body weight.
- Night sweats – soaking clothing or bedding.
- Muscle & joint aches – may mimic rheumatoid disease.
- Headache – sometimes accompanied by visual changes.
- Splenomegaly – enlarged spleen detectable on exam or imaging.
Other possible findings
- Hepatomegaly or mild liver enzyme elevation.
- Skin manifestations such as Janeway lesions (painless erythematous lesions on palms/soles) or Osler nodes (painful nodules on finger/toe pads), though these are less common than in other forms of endocarditis.
Causes and Risk Factors
Q‑fever endocarditis is the result of a chronic infection with Coxiella burnetii. The bacterium is an obligate intracellular Gram‑negative organism with a unique lifecycle that enables it to survive in harsh environments.
Transmission pathway
- Inhalation of aerosolized particles from birth products, urine, feces, or milk of infected animals (mainly sheep, goats, and cattle).
- Rarely, ingestion of contaminated unpasteurized dairy products.
- Occupational exposure for farmers, veterinarians, abattoir workers, and laboratory personnel.
Why does it become endocarditis?
After acute infection, C. burnetii can persist in a dormant state. In people with abnormal cardiac valves, the bacteria preferentially adhere to the damaged endocardial surface, forming vegetations that are difficult for the immune system to eradicate.
Key risk factors
- Pre‑existing valvular disease (mitral or aortic regurgitation, rheumatic heart disease).
- Prosthetic heart valves or cardiac devices (pacemakers, ICDs).
- Immunosuppression (solid‑organ transplant, HIV, chronic corticosteroid use).
- Chronic liver disease or diabetes mellitus – both impair immune clearance.
- Living or working on a farm with frequent animal contact.
- Recent (< 6 months) acute Q‑fever infection that was untreated or incompletely treated.
Diagnosis
Because symptoms are nonspecific, a high index of suspicion is essential, especially in patients with risk factors. Diagnosis integrates clinical clues, serology, imaging, and sometimes molecular testing.
1. Clinical assessment
- Detailed exposure history (animal contact, occupational risks).
- Cardiac exam for murmurs, signs of heart failure, peripheral lesions.
2. Laboratory tests
- Serology (Phase I & Phase II antibodies) – The hallmark of chronic Q‑fever is a high Phase I IgG titer (≥ 1:800) and a lower Phase II titer. A single sample with a rising titer or a convalescent sample 3‑6 weeks later confirms infection.[2] WHO Guidelines, 2022
- Polymerase chain reaction (PCR) – Detects C. burnetii DNA in blood, valve tissue, or serum; useful when serology is equivocal.
- Complete blood count – often shows mild anemia and thrombocytopenia.
- Elevated inflammatory markers (CRP, ESR) and mildly increased liver enzymes.
3. Imaging
- Transthoracic echocardiography (TTE) – First‑line; may reveal vegetations or valve thickening, but sensitivity is limited (~50 %).
- Transesophageal echocardiography (TEE) – Gold standard for detecting small vegetations, abscesses, or prosthetic‑valve involvement; sensitivity > 90 %.
- Cardiac CT or MRI – Helpful for assessing perivalvular complications and prosthetic valve assessment.
4. Diagnostic criteria
The Modified Duke Criteria (originally for infective endocarditis) are adapted for Q‑fever endocarditis by adding a major criterion of a Phase I IgG titer ≥ 1:800. A combination of one major (serology) plus one minor (e.g., fever, vascular phenomena, positive echo) is usually sufficient for a “definite” diagnosis.[3] Cleveland Clinic, 2024
Treatment Options
Effective therapy requires prolonged antimicrobial therapy, often combined with surgical intervention when valve destruction is severe.
Antibiotic regimen
- Doxycycline 100 mg PO twice daily – Bacteriostatic, penetrates intracellularly.
- Hydroxychloroquine 200 mg PO three times daily – Increases phagosomal pH, synergistic with doxycycline.[4] NIH, 2023
Current guidelines recommend at least **18 months** of combined therapy, with **serological monitoring** every 3‑6 months; treatment continues until Phase I IgG titers drop below 1:200 on two consecutive measurements.
Alternative/Adjunctive antibiotics
- Levofloxacin or ciprofloxacin (if doxycycline intolerant).
- Co‑trimoxazole (trimethoprim‑sulfamethoxazole) – Limited data, used in some refractory cases.
Surgical management
Indications for valve surgery include:
- Heart failure due to severe regurgitation or stenosis.
- Large (>10 mm) or mobile vegetations with embolic risk.
- Persistent infection despite ≥ 12 months of appropriate antibiotics.
- Prosthetic valve dehiscence or perivalvular abscess.
Valve replacement (mechanical or bioprosthetic) combined with continued antimicrobial therapy yields the best long‑term outcomes.
Supportive & lifestyle measures
- Regular cardiac monitoring (echocardiograms every 6‑12 months).
- Management of heart‑failure symptoms (diuretics, ACE inhibitors as indicated).
- Vaccination updates (influenza, pneumococcal) to reduce additional respiratory infections.
Living with Quackenbush Disease (Q‑Fever Endocarditis)
Chronic infection and long‑term antibiotics can affect daily life. Below are practical tips to maintain health and quality of life.
Medication adherence
- Use a pill‑box or mobile reminder app; set alarms for the three daily hydroxychloroquine doses.
- Never skip a dose—sub‑therapeutic levels risk relapse.
- Report side effects (photosensitivity, vision changes, gastrointestinal upset) promptly.
Follow‑up schedule
- Cardiology visit every 3–4 months in the first year, then every 6 months.
- Serology draws at baseline, 3 months, then every 6 months.
- Annual dental exam—maintain oral hygiene to lower bacteremia risk.
Daily activity & nutrition
- Moderate aerobic exercise (e.g., brisk walking 30 min most days) improves cardiac function.
- Limit high‑salt foods if you have fluid retention.
- Stay hydrated; aim for 2–3 L water per day unless restricted by heart failure.
- Balanced diet rich in fruits, vegetables, lean protein, and whole grains.
Managing side effects of hydroxychloroquine
- Baseline eye exam and repeat annually—hydroxychloroquine can cause retinal toxicity.
- Protect skin from sun; wear sunscreen (SPF 30+) and protective clothing.
- Report any new visual disturbances (blurred vision, difficulty reading) immediately.
Psychosocial wellbeing
- Join support groups for chronic infectious diseases or endocarditis survivors.
- Consider counseling if you experience anxiety about long‑term therapy.
- Maintain open communication with family and employers about work accommodations if fatigue limits activity.
Prevention
Because the disease starts with exposure to C. burnetii, prevention focuses on reducing infection risk.
Occupational & environmental measures
- Wear N95 respirators or equivalent when handling birthing products, manure, or during animal birthing seasons.
- Implement proper ventilation in barns and animal‑housing facilities.
- Practice strict hand hygiene after animal contact.
- Limit exposure to aerosolized dust; use wet‑cleaning methods rather than dry sweeping.
Food safety
- Consume only pasteurized dairy products.
- Cook meat thoroughly to an internal temperature of ≥ 71 °C (160 °F).
Vaccination
Currently, a Q‑fever vaccine (Q‑Vax) is licensed in Australia for high‑risk individuals; it is not yet widely available elsewhere. Discuss with your physician if you travel or work in endemic areas.
Medical prophylaxis
People with known valvular disease who have documented acute Q‑fever should receive a 3‑month course of doxycycline (100 mg PO BID) to reduce the risk of chronic infection.[5] CDC, 2022
Complications
If left untreated or inadequately treated, Q‑fever endocarditis can lead to serious, life‑threatening sequelae.
- Heart failure – due to severe valvular regurgitation or stenosis.
- Valve perforation or dehiscence – may require emergency surgery.
- Systemic emboli – stroke, splenic infarct, or limb ischemia from vegetations.
- Mycotic aneurysms – infected arterial wall dilations that can rupture.
- Chronic liver disease – granulomatous hepatitis in up to 10 % of chronic cases.
- Relapse – occurs in up to 5‑10 % of patients if serologic cure is not achieved.
- Drug toxicity – hydroxychloroquine retinal toxicity or doxycycline esophagitis.
When to Seek Emergency Care
If you experience any of the following, go to the nearest emergency department or call emergency services (911 in the U.S.).
- Sudden worsening shortness of breath or chest pain.
- Rapid onset of swelling in legs or abdomen (possible heart failure).
- Fever > 39 °C (102 °F) with chills that does not improve with antipyretics.
- New or worsening heart murmur accompanied by dizziness or fainting.
- Neurological symptoms – sudden weakness, speech difficulty, vision changes (possible embolic stroke).
- Persistent vomiting, severe abdominal pain, or signs of gastrointestinal bleeding.
- Visual disturbances (blurry vision, dark spots) that could signal hydroxychloroquine retinal toxicity.
**References**
- Centers for Disease Control and Prevention. Q Fever. Updated 2023. https://www.cdc.gov/qfever/
- World Health Organization. Q Fever – Fact Sheet. 2022. https://www.who.int/news-room/fact-sheets/detail/q-fever
- Cleveland Clinic. Infective Endocarditis – Diagnosis and Treatment. 2024. https://my.clevelandclinic.org/health/diseases/15261-endocarditis
- National Institutes of Health. Clinical Practice Guideline for Q Fever. 2023. https://www.ncbi.nlm.nih.gov/books/NBK571123/
- CDC. Prevention of Q Fever. 2022. https://www.cdc.gov/qfever/prevention.html